Antitumor therapy mediated by 5-fluorocytosine and a recombinant fusion protein containing TSG-6 hyaluronan binding domain and yeast cytosine deaminase

Molecular Pharmaceutics

Volumn 6, Issue 3, 2009, Pages 801-812

  Park, Joshua I ^a   Cao, Limin ^a   Platt, Virginia M ^a   Huang, Zhaohua ^a   Stull, Robert A ^a   Dy, Edward E ^a   Sperinde, Jeffrey J ^a   Yokoyama, Jennifer S ^a   Szoka Jr , Francis C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Drug delivery; Enzyme prodrug therapy; Protein engineering; Tumor matrix

Indexed keywords

CYTOSINE DEAMINASE; DRINKING WATER; FLUCYTOSINE; FLUOROURACIL; HYALURONIC ACID; HYBRID PROTEIN; LINK CYTOSINE DEAMINASE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CHELATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG BINDING; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN DOMAIN; SURFACE PLASMON RESONANCE;

ADENOCARCINOMA; ANIMALS; COLONIC NEOPLASMS; CYTOSINE DEAMINASE; FEMALE; FLUCYTOSINE; FLUOROURACIL; HYALURONIC ACID; HYDROGEN-ION CONCENTRATION; MICE; MICE, INBRED BALB C; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE;

EID: 67249100785     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800013c     Document Type: Article

References (57)

1. Senter, P. D.; Springer, C. J. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Delivery Rev. 2001, 53, 247-264.
2. O'Connor, S. W.; Bale, W. F. Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors. Cancer Res. 1984, 44, 3719-3723. (Pubitemid 14041580)
3. Bagshawe, K. D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer 1987, 56, 531-532. (Pubitemid 17165643)
4. Senter, P. D.; Su, P. C.; Katsuragi, T.; Sakai, T.; Cosand, W. L.; Hellstrom, I.; Hellstrom, K. E. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjugate Chem. 1991, 2, 447-451.
5. Wallace, P. M.; MacMaster, J. F.; Smith, V. F.; Kerr, D. E.; Senter, P. D.; Cosand, W. L. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res. 1994, 54, 2719-2723. (Pubitemid 24173764)
6. Kievit, E.; Bershad, E.; Ng, E.; Sethna, P.; Dev, I.; Lawrence, T. S.; Rehemtulla, A. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999, 59, 1417-1421. (Pubitemid 29160102)
7. Miller, C. R.; Williams, C. R.; Buchsbaum, D. J.; Gillespie, G. Y. Intratumoral 5-fluorouracil produced by cytosine deaminase/5- fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002, 62, 773-780. (Pubitemid 34126953)
8. Kambara, H.; Tamiya, T.; Ono, Y.; Ohtsuka, S.; Terada, K.; Adachi, Y.; Ichikawa, T.; Hamada, H.; Ohmoto, T. Combined radiation and gene therapy for brain tumors with adenovirus-mediated transfer of cytosine deaminase and uracil phosphoribosyltransferase genes. Cancer Gene Ther. 2002, 9, 840-845.
9. Deckert, P. M.; Renner, C.; Cohen, L. S.; Jungbluth, A.; Ritter, G.; Bertino, J. R.; Old, L. J.; Welt, S. A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy. Br. J. Cancer 2003, 88, 937-939. (Pubitemid 36520883)
10. Tai, C. K.; Wang, W. J.; Chen, T. C.; Kasahara, N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol. Ther. 2005, 12, 842-851.
11. Alderson, R. F.; Toki, B. E.; Roberge, M.; Geng, W.; Basler, J.; Chin, R.; Liu, A.; Ueda, R.; Hodges, D.; Escandon, E.; Chen, T.; Kanavarioti, T.; Babe, L.; Senter, P. D.; Fox, J. A.; Schellenberger, V. Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). Bioconjugate Chem. 2006, 17, 410-418.
12. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712. (Pubitemid 19147683)
13. Greco, O.; Dachs, G. U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol. 2001, 187, 22-36.
14. Platt, V. M.; Szoka, F. C., Jr. Anticancer therapeutics: targeting molecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharmaceutics 2008, 5, 474-486.
15. Fraser, J. R.; Laurent, T. C.; Laurent, U. B. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 1997, 242, 27-33.
16. Itano, N.; Sawai, T.; Miyaishi, O.; Kimata, K. Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res. 1999, 59, 2499-2504. (Pubitemid 29242303)
17. Kosaki, R.; Watanabe, K.; Yamaguchi, Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res. 1999, 59, 1141-1145. (Pubitemid 29135978)
18. Toole, B. P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4, 528-539.
19. Anttila, M. A.; Tammi, R. H.; Tammi, M. I.; Syrjanen, K. J.; Saarikoski, S. V.; Kosma, V. M. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res. 2000, 60, 150-155. (Pubitemid 30058745)
20. Auvinen, P.; Tammi, R.; Parkkinen, J.; Tammi, M.; Agren, U.; Johansson, R.; Hirvikoski, P.; Eskelinen, M.; Kosma, V. M. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 2000, 156, 529-536.
21. Olumi, A. F.; Grossfeld, G. D.; Hayward, S. W.; Carroll, P. R.; Tlsty, T. D.; Cunha, G. R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59, 5002-5011. (Pubitemid 29472907)
22. Ahrens, T.; Sleeman, J. P.; Schempp, C. M.; Howells, N.; Hofmann, M.; Ponta, H.; Herrlich, P.; Simon, J. C. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene 2001, 20, 3399-3408. (Pubitemid 32588988)
23. Peterson, R. M.; Yu, Q.; Stamenkovic, I.; Toole, B. P. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am. J. Pathol. 2000, 156, 2159-2167.
24. Mummert, M. E.; Mummert, D. I.; Ellinger, L.; Takashima, A. Functional roles of hyaluronan in B16-F10 melanoma growth and experimental metastasis in mice. Mol. Cancer. Ther. 2003, 2, 295-300.
25. Xu, X. M.; Chen, Y.; Chen, J.; Yang, S.; Gao, F.; Underhill, C. B.; Creswell, K.; Zhang, L. A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res. 2003, 63, 5685-5690. (Pubitemid 37203377)
26. Day, A. J.; Prestwich, G. D. Hyaluronan-binding proteins: tying up the giant. J. Biol. Chem. 2002, 277, 4585-4588.
27. Blundell, C. D.; Almond, A.; Mahoney, D. J.; DeAngelis, P. L.; Campbell, I. D.; Day, A. J. Towards a structure for a TSG-6 hyaluronan complex by modeling and NMR spectroscopy: insights into other members of the link module superfamily. J. Biol. Chem. 2005, 280, 18189-18201.
28. Banerji, S.; Wright, A. J.; Noble, M.; Mahoney, D. J.; Campbell, I. D.; Day, A. J.; Jackson, D. G. Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nat. Struct. Mol. Biol. 2007, 14, 234-239.
29. Lesley, J.; English, N. M.; Gal, I.; Mikecz, K.; Day, A. J.; Hyman, R. Hyaluronan binding properties of a CD44 chimera containing the link module of TSG-6. J. Biol. Chem. 2002, 277, 26600-26608.
30. Cutler, R. E.; Blair, A. D.; Kelly, M. R. Flucytosine kinetics in subjects with normal and impaired renal function. Clin. Pharmacol. Ther. 1978, 24, 333-342.
31. Kirchhoff, W. H. Exam: A Two-State Thermodynamic Analysis Program; NIST Tech. Note 1401; U.S. Government Printing Office: Washington, DC 1993; pp 1-103.
32. Ruhela, D.; Riviere, K.; Szoka, F. C., Jr. Efficient synthesis of an aldehyde functionalized hyaluronic acid and its application in the preparation of hyaluronan-lipid conjugates. Bioconjugate Chem. 2006, 17, 1360-1363.
33. Asai, T.; Trinh, R.; Ng, P. P.; Penichet, M. L.; Wims, L. A.; Morrison, S. L. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomol. Eng. 2005, 21, 145-155.
34. Ireton, G. C.; Black, M. E.; Stoddard, B. L. The 1.14 A crystal structure of yeast cytosine deaminase: evolution of nucleotide salvage enzymes and implications for genetic chemotherapy. Structure 2003, 11, 961-972. (Pubitemid 36966785)
35. Ko, T. P.; Lin, J. J.; Hu, C. Y.; Hsu, Y. H.; Wang, A. H.; Liaw, S. H. Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution. J. Biol. Chem. 2003, 278, 19111-19117.
36. Xiong, M. P.; Kwon, G. S. PEGylation of yeast cytosine deaminase for pretargeting. J. Pharm. Sci. 2005, 94, 1249-1258.
37. Korkegian, A.; Black, M. E.; Baker, D.; Stoddard, B. L. Computational thermostabilization of an enzyme. Science 2005, 308, 857-860. (Pubitemid 40629266)
38. Kahmann, J. D.; O'Brien, R.; Werner, J. M.; Heinegard, D.; Ladbury, J. E.; Campbell, I. D.; Day, A. J. Localization and characterization of the hyaluronan-binding site on the link module from human TSG-6. Structure 2000, 8, 763-774. (Pubitemid 30469994)
39. Gerweck, L. E. Tumor pH: implications for treatment and novel drug design. Semin. Radiat. Oncol. 1998, 8, 176-182.
40. Huang, Z.; Park, J. I.; Watson, D. S.; Hwang, P.; Szoka, F. C., Jr. Facile synthesis of multivalent nitrilotriacetic acid (NTA) and NTA conjugates for analytical and drug delivery applications. Bioconjugate Chem. 2006, 17, 1592-1600.
41. Day, A. J.; Aplin, R. T.; Willis, A. C. Overexpression, purification, and refolding of link module from human TSG-6 in Escherichia coli: effect of temperature, media, and mutagenesis on lysine misincorporation at arginine AGA codons. Protein Expression Purif. 1996, 8, 1-16. (Pubitemid 26326208)
42. Kahmann, J. D.; Koruth, R.; Day, A. J. Method for quantitative refolding of the link module from human TSG-6. Protein Expression Purif. 1997, 9, 315-318. (Pubitemid 27210699)
43. Banerji, S.; Day, A. J.; Kahmann, J. D.; Jackson, D. G. Characterization of a functional hyaluronan-binding domain from the human CD44 molecule expressed in Escherichia coli. Protein Expression Purif. 1998, 14, 371-381. (Pubitemid 29020371)
44. Chang, T. S.; Wan, H. M.; Chen, C. C.; Giridhar, R.; Wu, W. T. Fusion protein of the hyaluronan binding domain from human TSG-6 with luciferase for assay of hyaluronan. Biotechnol. Lett. 2003, 25, 1037-1040.
45. Mahoney, D. J.; Blundell, C. D.; Day, A. J. Mapping the hyaluronan-binding site on the Link module from human tumor necrosis factor-stimulated gene-6 by site-directed mutagenesis. J. Biol. Chem. 2001, 276, 22764-22771.
46. Evrard, A.; Cuq, P.; Robert, B.; Vian, L.; Pelegrin, A.; Cano, J. P. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study. Int. J. Cancer 1999, 80, 465-470. (Pubitemid 29019637)
47. Bourquin, C.; Schreiber, S.; Beck, S.; Hartmann, G.; Endres, S. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int. J. Cancer 2006, 118, 2790-2795. (Pubitemid 43673358)
48. Gavelli, A.; Baque, P.; Brossettej, N.; Bourgeon, A.; Staccini, P.; Rossi, B.; Pierrefite-Carle, V. Per os administration of 5-fluorocytosine is effective in the regression of CD-expressing liver metastases in rats. Int. J. Mol. Med. 2004, 14, 323-325.
49. Larsen, R. A.; Bauer, M.; Weiner, J. M.; Diamond, D. M.; Leal, M. E.; Ding, J. C.; Rinaldi, M. G.; Graybill, J. R. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob. Agents Chemother. 1996, 40, 2178-2182.
50. Stegman, L. D.; Rehemtulla, A.; Beattie, B.; Kievit, E.; Lawrence, T. S.; Blasberg, R. G.; Tjuvajev, J. G.; Ross, B. D. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9821-9826.
51. Kerr, D. E.; Garrigues, U. S.; Wallace, P. M.; Hellstrom, K. E.; Hellstrom, I.; Senter, P. D. Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate. Bioconjugate Chem. 1993, 4, 353-357.
52. Coelho, V.; Dernedde, J.; Petrausch, U.; Panjideh, H.; Fuchs, H.; Menzel, C.; Dubel, S.; Keilholz, U.; Thiel, E.; Deckert, P. M. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. Int. J. Oncol. 2007, 31, 951-957.
53. Bobo, R. H.; Laske, D. W.; Akbasak, A.; Morrison, P. F.; Dedrick, R. L.; Oldfield, E. H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 2076-2080.
54. Voges, J.; Reszka, R.; Gossmann, A.; Dittmar, C.; Richter, R.; Garlip, G.; Kracht, L.; Coenen, H. H.; Sturm, V.; Wienhard, K.; Heiss, W. D.; Jacobs, A. H. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. 2003, 54, 479-487.
55. Voges, J.; Weber, F.; Reszka, R.; Sturm, V.; Jacobs, A.; Heiss, W. D.; Wiestler, O.; Kapp, J. F. Clinical protocol. Liposomal gene therapy with the herpes simplex thymidine kinase gene/ganciclovir system for the treatment of glioblastoma multiforme. Hum. Gene Ther. 2002, 13, 675-685.
56. MacKay, J. A.; Deen, D. F.; Szoka, F. C., Jr. Brain Res. 2005, 1035, 139-153, Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating.
57. Gillies, E. R.; Dy, E.; Frechet, J. M.; Szoka, F. C. Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. Mol. Pharmaceutics 2005, 2, 129-138.